Mostrar el registro sencillo del ítem
dc.contributor.author | Gasent Blesa, J. M. | es_ES |
dc.contributor.author | Giner Marco, V. | es_ES |
dc.contributor.author | Giner-Bosch, Vicent | es_ES |
dc.contributor.author | Cerezuela Fuentes, Pablo | es_ES |
dc.contributor.author | Alberola Candel, Vicente | es_ES |
dc.date.accessioned | 2020-03-30T07:21:40Z | |
dc.date.available | 2020-03-30T07:21:40Z | |
dc.date.issued | 2011 | es_ES |
dc.identifier.issn | 0277-3732 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/139762 | |
dc.description.abstract | [EN] Introduction: Docetaxel plus prednisone is the current standard of care in first-line chemotherapy for metastatic hormone-refractory prostate cancer. However, there is no agent proven as effective after progression to standard docetaxel-based therapy. Platins and capecitabine have shown activity in this setting. Patients and Methods: A total of 14 patients were included in this prospective, single-center trial. All patients had progressed to first-line docetaxel-based treatment. Patients received oxaliplatin 100 mg/sqm on D1 and capecitabine 1000 mg/sqm/bid on days 1 to 14 every 21 days. Results: Median number of cycles was 3. No unexpected toxicity was observed. Only grade 3 toxicity reported was grade 3 anemia. Of the 14 patients, 3 presented grade 2 neuropathy which was spontaneously resolved. Prostate-specific antigenresponse rate was 57%, with a median time to progression of 14.5 weeks, and overall survival of 24 weeks. Conclusions: In the second-line setting, after receiving docetaxel-based chemotherapy, the combination of oxaliplatin and capecitabine offers promising activity with an excellent safety profile. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Lippincott Williams & Wilkins | es_ES |
dc.relation.ispartof | American Journal of Clinical Oncology | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | Prostate cancer | es_ES |
dc.subject | Second line | es_ES |
dc.subject | Chemotherapy | es_ES |
dc.subject | Hormono-refractory | es_ES |
dc.subject.classification | ESTADISTICA E INVESTIGACION OPERATIVA | es_ES |
dc.title | Phase II Trial of Oxaliplatin and Capecitabine After Progression to First-Line Chemotherapy in Androgen-Independent Prostate Cancer Patients | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1097/COC.0b013e3181d6b453 | es_ES |
dc.rights.accessRights | Cerrado | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Departamento de Estadística e Investigación Operativa Aplicadas y Calidad - Departament d'Estadística i Investigació Operativa Aplicades i Qualitat | es_ES |
dc.description.bibliographicCitation | Gasent Blesa, JM.; Giner Marco, V.; Giner-Bosch, V.; Cerezuela Fuentes, P.; Alberola Candel, V. (2011). Phase II Trial of Oxaliplatin and Capecitabine After Progression to First-Line Chemotherapy in Androgen-Independent Prostate Cancer Patients. American Journal of Clinical Oncology. 34(2):1-5. https://doi.org/10.1097/COC.0b013e3181d6b453 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1097/COC.0b013e3181d6b453 | es_ES |
dc.description.upvformatpinicio | 1 | es_ES |
dc.description.upvformatpfin | 5 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 34 | es_ES |
dc.description.issue | 2 | es_ES |
dc.relation.pasarela | S\38724 | es_ES |